Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Conversion From Vicodin to Butrans in Osteoarthritis Pain
NCT00312572Phase 3Completed
- Sponsor
- Purdue Pharma
- Start
- Jun 2003
- Primary completion
- Jul 2004
- Modality
- Orthosteric Ligands, Inhalation Devices
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of v1003 in osteoarthritis (OA) (2 arms), sponsored by Purdue Pharma. Primary endpoint: The Percentage of Subjects Who Completed the 14-day Double-blind Phase. Started Jun 2003; status: completed.
02
Drugs
v1003
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT00312572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00312572.